J Zhou1,2, M V Reddy3, B K J Wilson3, D A Blair4, A Taha5,6, C M Frampton7, R A Eiholzer2, P Y C Gan8, F Ziad9, Z Thotathil10, S Kirs6, N A Hung2, J A Royds2, T L Slatter2. 1. From the Departments of Radiology (J.Z., M.V.R., B.K.J.W.) jean.zhou@southerndhb.govt.nz. 2. Department of Pathology (J.Z., R.A.E., N.A.H., J.A.R., T.L.S.). 3. From the Departments of Radiology (J.Z., M.V.R., B.K.J.W.). 4. Departments of Radiology (D.A.B.). 5. Neurosurgery (A.T.), Southern District Health Board, Dunedin, New Zealand. 6. Surgical Sciences (A.T., S.K.), Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. 7. Department of Medicine (C.M.F.), University of Otago, Christchurch, New Zealand. 8. Neurosurgery (P.Y.C.G.). 9. Pathology (F.Z.). 10. Medical Oncology (Z.T.), Waikato District Health Board, Hamilton, New Zealand.
Abstract
BACKGROUND AND PURPOSE: In glioblastoma, tumor-associated macrophages have tumor-promoting properties. This study determined whether routine MR imaging features could predict molecular subtypes of glioblastoma that differ in the content of tumor-associated macrophages. MATERIALS AND METHODS: Seven internally derived MR imaging features were assessed in 180 patients, and 25 features from the Visually AcceSAble Rembrandt Images feature set were assessed in 164 patients. Glioblastomas were divided into subtypes based on the telomere maintenance mechanism: alternative lengthening of telomeres positive (ALT+) and negative (ALT-) and the content of tumor-associated macrophages (with [M+] or without [M-] a high content of macrophages). The 3 most frequent subtypes (ALT+/M-, ALT-/M+, and ALT-/M-) were correlated with MR imaging features and clinical parameters. The fourth group (ALT+/M+) did not have enough cases for correlation with MR imaging features. RESULTS: Tumors with a regular margin and those lacking a fungating margin, an expansive T1/FLAIR ratio, and reduced ependymal extension were more frequent in the subgroup of ALT+/M- (P < .05). Radiologic necrosis, lack of cystic component (by both criteria), and extensive peritumoral edema were more frequent in ALT-/M+ tumors (P < .05). Multivariate testing with a Cox regression analysis found the cystic imaging feature was additive to tumor subtype, and O6-methylguanine methyltransferase (MGMT) status to predict improved patient survival (P < .05). CONCLUSIONS: Glioblastomas with tumor-associated macrophages are associated with routine MR imaging features consistent with these tumors being more aggressive. Inclusion of cystic change with molecular subtypes and MGMT status provided a better estimate of survival.
BACKGROUND AND PURPOSE: In glioblastoma, tumor-associated macrophages have tumor-promoting properties. This study determined whether routine MR imaging features could predict molecular subtypes of glioblastoma that differ in the content of tumor-associated macrophages. MATERIALS AND METHODS: Seven internally derived MR imaging features were assessed in 180 patients, and 25 features from the Visually AcceSAble Rembrandt Images feature set were assessed in 164 patients. Glioblastomas were divided into subtypes based on the telomere maintenance mechanism: alternative lengthening of telomeres positive (ALT+) and negative (ALT-) and the content of tumor-associated macrophages (with [M+] or without [M-] a high content of macrophages). The 3 most frequent subtypes (ALT+/M-, ALT-/M+, and ALT-/M-) were correlated with MR imaging features and clinical parameters. The fourth group (ALT+/M+) did not have enough cases for correlation with MR imaging features. RESULTS:Tumors with a regular margin and those lacking a fungating margin, an expansive T1/FLAIR ratio, and reduced ependymal extension were more frequent in the subgroup of ALT+/M- (P < .05). Radiologic necrosis, lack of cystic component (by both criteria), and extensive peritumoral edema were more frequent in ALT-/M+ tumors (P < .05). Multivariate testing with a Cox regression analysis found the cystic imaging feature was additive to tumor subtype, and O6-methylguanine methyltransferase (MGMT) status to predict improved patient survival (P < .05). CONCLUSIONS:Glioblastomas with tumor-associated macrophages are associated with routine MR imaging features consistent with these tumors being more aggressive. Inclusion of cystic change with molecular subtypes and MGMT status provided a better estimate of survival.
Authors: Kerrie L McDonald; Julie McDonnell; Alessandra Muntoni; Jeremy D Henson; Monika E Hegi; Andreas von Deimling; Helen R Wheeler; Ray J Cook; Michael T Biggs; Nicholas S Little; Bruce G Robinson; Roger R Reddel; Janice A Royds Journal: J Neuropathol Exp Neurol Date: 2010-07 Impact factor: 3.685
Authors: Manish Aghi; Paola Gaviani; John W Henson; Tracy T Batchelor; David N Louis; Fred G Barker Journal: Clin Cancer Res Date: 2005-12-15 Impact factor: 12.531
Authors: Gurvinder Kaur; Orin Bloch; Brian J Jian; Rajwant Kaur; Michael E Sughrue; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Susan M Chang; Andrew T Parsa Journal: J Neurosurg Date: 2011-07-15 Impact factor: 5.115
Authors: Whitney B Pope; James Sayre; Alla Perlina; J Pablo Villablanca; Paul S Mischel; Timothy F Cloughesy Journal: AJNR Am J Neuroradiol Date: 2005 Nov-Dec Impact factor: 3.825
Authors: A Pierallini; M Bonamini; M F Osti; P Pantano; F Palmeggiani; A Santoro; R Maurizi Enrici; L Bozzao Journal: Neuroradiology Date: 1996-05 Impact factor: 2.804
Authors: Marcos V C Maldaun; Dima Suki; Frederick F Lang; Sujit Prabhu; Weiming Shi; Gregory N Fuller; David M Wildrick; Raymond Sawaya Journal: J Neurosurg Date: 2004-01 Impact factor: 5.115
Authors: Sylvia Drabycz; Gloria Roldán; Paula de Robles; Daniel Adler; John B McIntyre; Anthony M Magliocco; J Gregory Cairncross; J Ross Mitchell Journal: Neuroimage Date: 2009-09-28 Impact factor: 6.556
Authors: Noelyn A Hung; Ramona A Eiholzer; Stenar Kirs; Jean Zhou; Kirsten Ward-Hartstonge; Anna K Wiles; Chris M Frampton; Ahmad Taha; Janice A Royds; Tania L Slatter Journal: Mod Pathol Date: 2016-01-15 Impact factor: 7.842
Authors: Janice A Royds; Anna P Pilbrow; Antonio Ahn; Helen R Morrin; Chris Frampton; I Alasdair Russell; Christine S Moravec; Wendy E Sweet; W H Wilson Tang; Margaret J Currie; Noelyn A Hung; Tania L Slatter Journal: Front Oncol Date: 2016-01-21 Impact factor: 6.244
Authors: Amir Nazem; Samantha C Guiry; MacLean Nasrallah; Ali Nabavizadeh; Mehrdad Pourfathi; Jeffrey B Ware; Hannah Anderson; Srikant Kamesh Iyer; Brianna F Moon; Yi Fan; Walter R Witschey; Rahim Rizi; Stephen J Bagley; Arati Desai; Donald M O'Rourke; Steven Brem Journal: J Neurooncol Date: 2022-01-19 Impact factor: 4.130
Authors: Marina Kazantseva; Ramona A Eiholzer; Sunali Mehta; Ahmad Taha; Sara Bowie; Imogen Roth; Jean Zhou; Sebastien M Joruiz; Janice A Royds; Noelyn A Hung; Tania L Slatter; Antony W Braithwaite Journal: J Pathol Date: 2018-07-31 Impact factor: 7.996
Authors: Lee Curtin; Paula Whitmire; Cassandra R Rickertsen; Gina L Mazza; Peter Canoll; Sandra K Johnston; Maciej M Mrugala; Kristin R Swanson; Leland S Hu Journal: Front Oncol Date: 2020-11-16 Impact factor: 5.738